Neurobiological Technologies, Inc. (NTII) Stock Price & Analysis
Neurobiological Technologies, Inc. (NTII) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 1,100 shares. Market capitalization is $2,701, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 00:15 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NTII.md
Key facts (NTII)
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +14.0%; 5Y -98.8% vs S&P 500 +76.9%.
Analysts (NTII)
Consensus None.
Total return (dividends reinvested) (NTII)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +0.0% | -98.8% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | +0.0% | -58.4% |
| Volatility (annualized) | 0.0% | 220.5% |
| Max drawdown | +0.0% (→) | -98.8% (Oct 2021→May 2022) |
NTII analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 00:15 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 1,100 shares |
| Market Cap | $2,701 |
| Exchange | PNK |
Technical Analysis (NTII)
Nexqual's technical model rates NTII "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 24, 2026 at 00:15 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (NTII)
Wall Street analysts rate NTII "None", per Nexqual as of October 24, 2026 at 00:15 UTC.
| Consensus Rating | None |
|---|
Earnings (NTII)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2009-03-31 | USD -0.01 vs est -0.15 ▲ beat |
Source: Nexqual, October 24, 2026 at 00:15 UTC.
Financials & Fundamentals (NTII)
| Total Revenue | $25.32M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | +76.97% |
| Profit Margin | +73.72% |
| ROE | +99.72% |
| Total Cash | $26.49M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 00:15 UTC.
Financial Health Score (NTII)
Nexqual rates Neurobiological Technologies, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 00:15 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $26M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M (TTM) |
| Efficiency | Strong — ROE 100% |
Ownership (NTII)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 27.02M |
| Short % of Float | +0.33% |
Source: Nexqual, October 24, 2026 at 00:15 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 00:15 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt